http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009221444-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f6dbd0c2f774a7e132763153fff3fbf |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B40-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-00 |
| filingDate | 2006-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e31bcfbd840ca5e650b5886086b0ccd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc2671660f52ca8ef483fbdb4202d382 |
| publicationDate | 2009-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009221444-A1 |
| titleOfInvention | Method for Identifying, Marking and Treating Epithelial Lung Tumour Cells and Means for Carrying Out Said Method |
| abstract | The bronchial carcinoma is the most common tumour found in humans world-wide and is in most cases beyond remedy. The invention relates to a method for identifying, marking and treating epithelial lung tumour cells, specifically of an adenocarcinoma, with the aid of novel treatment targets, and to means for carrying out said method. At the basis of the invention is the discovery that the expression of genes that code for CAM and ECM molecules is modified in c-raf and/or c-myc induced adenocarcinomas of the lung. Cell-adhesion proteins and extra-cellular matrix proteins constitute the treatment targets. According to the invention, a biological or biotechnological system is brought into contact with a dissolved substance that has an affinity to at least one of the following genes: ADAM19, Mmp12, Col18a1, Col15a1, CD44, Bsg, Itgb2, Itgax, Lamc2, Lamb3, Alcam, Cldn2, Cldn3, Cldn7, Krt1-18, Krt2-8, tacstd1, tacstd2, S100a1, S100a11, their variants, parts of said genes, their mRNA or their gene products, cleavage products derived from said genes, polypeptides or peptides, said substance being bound to a suitable marker. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018067119-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2773774-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9732151-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3738606-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013067051-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014302061-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015524051-A |
| priorityDate | 2005-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 677.